These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 30528042)

  • 41. Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis.
    Sakai T; Nishida Y; Hamada S; Koike H; Ikuta K; Ota T; Ishiguro N
    Diagn Pathol; 2017 Aug; 12(1):66. PubMed ID: 28851389
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Next-generation sequencing is highly sensitive for the detection of beta-catenin mutations in desmoid-type fibromatoses.
    Aitken SJ; Presneau N; Kalimuthu S; Dileo P; Berisha F; Tirabosco R; Amary MF; Flanagan AM
    Virchows Arch; 2015 Aug; 467(2):203-10. PubMed ID: 25838078
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nuclear TFE3 expression is a diagnostic marker for Desmoid-type fibromatosis.
    Zhou L; Xu H; Zhou J; Dong L; Zhang P; Yang X; Wang C
    Diagn Pathol; 2019 May; 14(1):34. PubMed ID: 31043173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinicopathological analysis of β-catenin and Axin-1 in solid pseudopapillary neoplasms of the pancreas.
    Huang SC; Ng KF; Yeh TS; Chang HC; Su CY; Chen TC
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S438-46. PubMed ID: 21769465
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Possible association between higher beta-catenin mRNA expression and mutated beta-catenin in sporadic desmoid tumors: real-time semiquantitative assay by TaqMan polymerase chain reaction.
    Saito T; Oda Y; Kawaguchi K; Tanaka K; Matsuda S; Tamiya S; Iwamoto Y; Tsuneyoshi M
    Lab Invest; 2002 Jan; 82(1):97-103. PubMed ID: 11796830
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis.
    Signoroni S; Frattini M; Negri T; Pastore E; Tamborini E; Casieri P; Orsenigo M; Da Riva L; Radice P; Sala P; Gronchi A; Bertario L; Pierotti MA; Pilotti S
    Clin Cancer Res; 2007 Sep; 13(17):5034-40. PubMed ID: 17785554
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel intra-genic large deletions of CTNNB1 gene identified in WT desmoid-type fibromatosis.
    Colombo C; Urbini M; Astolfi A; Collini P; Indio V; Belfiore A; Paielli N; Perrone F; Tarantino G; Palassini E; Fiore M; Pession A; Stacchiotti S; Pantaleo MA; Gronchi A
    Genes Chromosomes Cancer; 2018 Oct; 57(10):495-503. PubMed ID: 29901254
    [TBL] [Abstract][Full Text] [Related]  

  • 48. beta-catenin nuclear expression correlates with cyclin D1 overexpression in sporadic desmoid tumours.
    Saito T; Oda Y; Tanaka K; Matsuda S; Tamiya S; Iwamoto Y; Tsuneyoshi M
    J Pathol; 2001 Sep; 195(2):222-8. PubMed ID: 11592102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Abnormalities of the Wnt/β-catenin signalling pathway induce tumour progression in sporadic desmoid tumours: correlation between β-catenin widespread nuclear expression and VEGF overexpression.
    Matono H; Tamiya S; Yokoyama R; Saito T; Iwamoto Y; Tsuneyoshi M; Oda Y
    Histopathology; 2011 Sep; 59(3):368-75. PubMed ID: 22034877
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review.
    McLean TD; Duchi S; Di Bella C
    Target Oncol; 2022 May; 17(3):223-252. PubMed ID: 35446005
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neuromuscular Choristoma: Report of Five Cases With CTNNB1 Sequencing.
    Brandao ICS; de Souza FS; de Amoreira Gepp R; Martins BJAF; de Mendonca Cardoso M; Sollaci C; da Cunha IW; Kalil RK
    J Neuropathol Exp Neurol; 2021 Nov; 80(11):1068–1077. PubMed ID: 34718655
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Metabolomics Pilot Study on Desmoid Tumors and Novel Drug Candidates.
    Mercier KA; Al-Jazrawe M; Poon R; Acuff Z; Alman B
    Sci Rep; 2018 Jan; 8(1):584. PubMed ID: 29330550
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Wnt/β-Catenin Signaling Activation beyond Robust Nuclear β-Catenin Accumulation in Nondysplastic Barrett's Esophagus: Regulation via Dickkopf-1.
    Lyros O; Rafiee P; Nie L; Medda R; Jovanovic N; Otterson MF; Behmaram B; Gockel I; Mackinnon A; Shaker R
    Neoplasia; 2015 Jul; 17(7):598-611. PubMed ID: 26297437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activation of the Wnt/β-catenin pathway is common in wilms tumor, but rarely through β-catenin mutation and APC promoter methylation.
    Schweigert A; Fischer C; Mayr D; von Schweinitz D; Kappler R; Hubertus J
    Pediatr Surg Int; 2016 Dec; 32(12):1141-1146. PubMed ID: 27679509
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Superficial fibromas with CTNNB1 mutation.
    Kuntze A; Meliß RR; Ermert L; Falkenberg KD; Puller AC; Trautmann M; Hartmann W; Wardelmann E
    Genes Chromosomes Cancer; 2024 May; 63(5):e23247. PubMed ID: 38757718
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alteration in the Wnt/β-catenin signaling pathway in gastric neoplasias of fundic gland (chief cell predominant) type.
    Hidaka Y; Mitomi H; Saito T; Takahashi M; Lee SY; Matsumoto K; Yao T; Watanabe S
    Hum Pathol; 2013 Nov; 44(11):2438-48. PubMed ID: 24011952
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TGF-β and CTGF are Mitogenic Output Mediators of Wnt/β-Catenin Signaling in Desmoid Fibromatosis.
    Varghese S; Braggio DA; Gillespie J; Toland AE; Pollock R; Mayerson J; Scharschmidt T; Iwenofu OH
    Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):559-565. PubMed ID: 26894649
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors.
    Salas S; Chibon F; Noguchi T; Terrier P; Ranchere-Vince D; Lagarde P; Benard J; Forget S; Blanchard C; Dômont J; Bonvalot S; Guillou L; Leroux A; Mechine-Neuville A; Schöffski P; Laë M; Collin F; Verola O; Carbonnelle A; Vescovo L; Bui B; Brouste V; Sobol H; Aurias A; Coindre JM
    Genes Chromosomes Cancer; 2010 Jun; 49(6):560-8. PubMed ID: 20232483
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Spatio-temporal genetic heterogeneity of CTNNB1 mutations in sporadic desmoid type fibromatosis lesions.
    Doyen J; Duranton-Tanneur V; Hostein I; Karanian-Philippe M; Chevreau C; Breibach F; Coutts M; Dadone B; Saint-Paul MC; Gugenheim J; Duffaud F; Pedeutour F
    Virchows Arch; 2016 Mar; 468(3):369-74. PubMed ID: 26666421
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
    Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
    J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.